Consolidated Statements of Changes in Stockholders’ Deficit - USD ($)	Common Stock	Stock payable Amount	Additional Paid-in Capital Deficit	Total Accumulated Deficit	Mezzanine Equity	Total
Balance at Dec. 31, 2019			$ 44,465,702	$ (91,130,414)	$ 40,070,108	$ (46,664,712)
Balance (in Shares) at Dec. 31, 2019	4,298
Stock based compensation			261,469			261,469
Net loss				(6,192,370)		(6,192,370)
Balance at Dec. 31, 2020			44,727,171	(97,322,784)	40,070,108	(52,595,613)
Balance (in Shares) at Dec. 31, 2020	4,298
Stock based compensation			193,747			193,747
Warrants issued with notes			5,796,609			5,796,609
Issuance of Common Shares			23,450			23,450
Issuance of Common Shares (in Shares)	4,700
Preferred Stock conversion into common stock	$ 6		40,070,102		(40,070,108)	40,070,108
Preferred Stock conversion into common stock (in Shares)	618,687
Notes payable and accrued interest conversion into common stock	$ 6		10,639,610			10,639,616
Notes payable and accrued interest conversion into common stock (in Shares)	571,621
Preferred Stock C exchange for Nanomix Common Stock	$ (12)		(14,670,621)		14,670,633	(14,670,633)
Preferred Stock C exchange for Nanomix Common Stock (in Shares)	(1,199,306)
Merge with Boston Therapeutics	$ 5,300		(3,870,990)		963,964	(3,865,690)
Merge with Boston Therapeutics (in Shares)	5,300,084
Loss on debt modification			2,385,204			2,385,204
Nanomix common stock purchase			(202,188)			(202,188)
Nanomix options exercised		20,375				20,375
Net loss				(9,465,033)		(9,465,033)
Balance at Dec. 31, 2021	$ 5,300	$ 20,375	$ 85,092,094	$ (106,787,817)	$ 15,634,597	$ (21,670,048)
Balance (in Shares) at Dec. 31, 2021	5,300,084